Pharma News

Keep updating your pharma knowledge
14 Feb 2017

Case Analysis: Mead Johnson-Reckitt Benckiser Mega Deal

British consumer health giant Reckitt Benckiser agreed to buy pediatric nutrition manufacture  Mead Johnson Nutrition Company MJN for US$16.6 billion.

Reckitt Benckiser, which owns famous power brands like Strepsils, Durex, Lysol, Dettol and many more, plans to add Mead Johnson’s global brands Enfamil and Nutramigen as a new division within the company’s portfolio.

The transaction will also take Reckitt, whose brands include Durex condoms and Nurofen painkillers, into the baby-food market for the first time.

———-

Is the deal strategic fit for both the company?

The transaction will also take Reckitt, whose brands include Durex condoms and Nurofen painkillers, into the baby-food market for the first time.

This deal is win-win for both the company. The successful completion of the integration will lead to medium to long-term growth of 3–5% in global infant and children’s nutrition category of Mead Johnson, which is currently worth approximately $46 billion in annual sales. After an initial transitional period, Reckitt Benckiser expects to perform progressively toward achieving the upper end of this estimated range.

Reckitt Benckiser’s multi-geography supply chain infrastructure and distribution network should enhance Mead Johnson’s go-to-market capabilities. This apart, it will also accelerate Mead Johnson’s entry into new emerging geographies where Reckitt Benckiser already has an existing and deep understanding of local consumer health dynamics.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!